Christensen, B., Micic, D., Gibson, P. R., Yarur, A., Bellaguarda, E., Corsello, P., . . . Rubin, D. T. (2018). Vedolizumab in patients with concurrent primary sclerosing cholangitis and inflammatory bowel disease does not improve liver biochemistry but is safe and effective for the bowel disease. Aliment Pharmacol Ther.
Citação norma ChicagoChristensen, Britt, et al. "Vedolizumab in Patients With Concurrent Primary Sclerosing Cholangitis and Inflammatory Bowel Disease Does Not Improve Liver Biochemistry but Is Safe and Effective for the Bowel Disease." Aliment Pharmacol Ther 2018.
MLA CitationChristensen, Britt, et al. "Vedolizumab in Patients With Concurrent Primary Sclerosing Cholangitis and Inflammatory Bowel Disease Does Not Improve Liver Biochemistry but Is Safe and Effective for the Bowel Disease." Aliment Pharmacol Ther 2018.